Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors

  Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of
                                  Directors

PR Newswire

SAN DIEGO, March 14, 2013

SAN DIEGO, March 14, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc.
(NASDAQ: CADX), a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting, announced today the appointment of Stephen L.
Newman, M.D., to the company's board of directors.

"We are very pleased to welcome Dr. Newman to our board of directors. His
experience in the evolving sector of integrated delivery networks, significant
healthcare operations experience, and clinical background will be an
invaluable addition to our board as we seek to expand our portfolio of
products for use within the hospital setting," stated Cam Garner, Chairman of
Cadence.

Dr. Newman served in positions of increasing responsibility with Tenet
Healthcare Corporation (NYSE:THC), including as Vice Chairman from January
2012 until his retirement inJune 2012. Since joining Tenet in 1999, he also
served as Corporate Chief Operating Officer and Executive Vice President of
Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem,
California, and as Senior Vice President, Gulf States Region, of Tenet
HealthSystem. Prior to joining Tenet, Dr.Newmanheld executive positions
atColumbia/HCA, Inc., and served as Senior Vice President and Chief Medical
Officer of Touro Infirmary inNew Orleans. Earlier in his career, Dr. Newman
was an Associate Professor of Pediatrics and Medicine atWright State
UniversitySchool of Medicine, and Director of Gastroenterology and Nutrition
Support at Children's Medical Center inDayton, Ohio. Dr. Newman is currently
a member of the Labor, Education and Healthcare Council of the Federal Reserve
Bank of Atlanta, and a member of the Board of Directors of Optimer
Pharmaceuticals, Inc. and Hansen Medical, Inc. He holds a bachelor's degree
fromRutgers University, an M.B.A. fromTulane Universityand a medical degree
from theUniversity of Tennessee. Dr. Newman completed his internship,
residency and fellowship atEmory University School of Medicine, and has also
completed the Advanced Management Program at the University of Pennsylvania's
Wharton School of Business.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring,
in-licensing, developing and commercializing proprietary products principally
for use in the hospital setting. The current version of Cadence
Pharmaceuticals' corporate overview may be viewed on the Investors page of
www.cadencepharm.com under "Events & Presentations" by selecting "Corporate
Overview."

CADENCE^® and OFIRMEV® are registered trademarks of Cadence Pharmaceuticals,
Inc.



Contact: William R. LaRue              Kelli France
         SVP & Chief Financial Officer Media Relations
         Cadence Pharmaceuticals, Inc. WCG
         Phone: 858-436-1400           Phone: 415-946-1076

SOURCE Cadence Pharmaceuticals, Inc.

Website: http://www.cadencepharm.com
 
Press spacebar to pause and continue. Press esc to stop.